Inflammation News and Research

RSS

Concord grapes increase good cholesterol

Drinking Concord grape juice significantly increased HDL--the good cholesterol--and significantly lowered two markers of inflammation in people with stable coronary artery disease, according to results of a study presented in the November issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology.

16 Nov 2004

Keeping fit lowers C-Reactive protein in people with metabolic syndrome

In people with signs of metabolic syndrome, including high blood pressure, high triglycerides, high cholesterol, elevated blood glucose and obesity, physical activity appears to reduce a marker for inflammation which has been linked to heart disease

16 Nov 2004

Fluorescent protein tool may speed identification of molecular changes that reveal cells' inner workings

Scientists at Johns Hopkins and the University of Texas Medical Branch have created a new tool that easily reveals when and where a key cellular signal is active.

16 Nov 2004

Brain inflammation is a sign of autism

A new study by scientists at Johns Hopkins shows that brain inflammation is a sign of autism. The findings are reported in the online edition of Annals of Neurology, the scientific journal of the American Neurological Association.

15 Nov 2004

Sirolimus drug-coated stent causes less inflammation than bare metal stents

In the treatment of coronary artery disease, a sirolimus drug-coated stent causes less inflammation than bare metal stents, according to preliminary research presented at the American Heart Association annual meeting by Loyola University Health System, Maywood, Ill.

11 Nov 2004

Abbott's investigational anti-interleukin-12 fully human monoclonal antibody in Crohn's disease study

Results of a Phase II study of Abbott's ABT-874, a fully human anti-interleukin-12 (IL-12) monoclonal antibody, will appear tomorrow in the New England Journal of Medicine citing treatment with ABT-874 shows differences in response and remission in patients with active Crohn's disease compared to placebo, in one arm of the study.

10 Nov 2004

Metabolic syndrome associated with cognitive decline in elderly persons

Elderly individuals with the metabolic syndrome, a grouping of several common conditions including abdominal obesity, low level of high-density lipoprotein (HDL, the “good cholesterol”), hypertension, and high triglyceride and blood sugar levels, are more likely to experience cognitive impairment than those without this syndrome, according to a study in the November 10 issue of JAMA.

10 Nov 2004

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Berlex announced today that new laboratory results demonstrate that its modified version of the naturally occurring lipoxin molecule exerts potent anti-inflammatory and immunomodulatory effects in Crohn's disease in vivo models and may provide a promising new oral treatment.

9 Nov 2004

Walnut supplementation favorably affects cholesterol and other lipids that are signs of cardiovascular risk

A Penn State study has shown that a diet rich in alpha-linolenic acid from walnuts, walnut oil and flaxseed oil not only lowered bad cholesterol but also decreased markers for blood vessel inflammation in men and women representative of typical Americans at cardiovascular risk.

8 Nov 2004

Association between long-term air pollution exposure and the early stages of atherosclerosis

Air pollution may trigger and accelerate narrowing of carotid arteries, according to a study presented at the American Heart Association's Scientific Sessions 2004.

8 Nov 2004

Remicade (infliximab) is able to reverse the symptoms of rheumatoid arthritis

A new study published today in Arthritis & Rheumatism demonstrates that Remicade (infliximab) is able to reverse the symptoms of the debilitating disease rheumatoid arthritis (RA) in patients who are newly diagnosed.

5 Nov 2004

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

5 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004

Psoriasis trial enters final stage

Solbec Pharmaceuticals Ltd today announced the successful completion of the first two stages of the Phase I clinical trial of its lead compound, CoramsineTM (SBP002), for the treatment of psoriasis.

4 Nov 2004

Study reveals anti-arthritic effects of bee venom

Since ancient times, healers have practiced apitherapy, the use of honeybee products for curative purposes.

4 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

Possible treatment for the fatal lung disease idiopathic pulmonary fibrosis

They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. Now the treatment is undergoing clinical trials at Mayo Clinic.

2 Nov 2004

$73 million to tackle infectious diseases such as West Nile virus and influenza

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 14 contracts totaling more than $73 million to fund the Large-Scale Antibody and T Cell Epitope Discovery Program, an initiative aimed at quickly identifying the regions of selected infectious agents that elicit immune reactions.

1 Nov 2004

Gene found to defend against environmental pollutants and pulmonary emphysema

Researchers at the Johns Hopkins Bloomberg School of Public Health and other institutions have identified a “master gene” in mice that controls the action of 50 other genes whose products protect the lungs against environmental pollutants.

1 Nov 2004

New treatment option for patients who have moderately active ulcerative colitis

Results of a study presented today by a Mayo Clinic physician at the 69th Annual Scientific Meeting of the American College of Gastroenterology (ACG) in Orlando, Fla., offer a new treatment option for patients who have moderately active ulcerative colitis.

1 Nov 2004